Published in Science on June 19, 1992
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol (1997) 2.27
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol (1997) 1.66
Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol (1994) 1.32
HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol (2008) 1.29
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol (1998) 1.21
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol (1998) 1.19
Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. J Virol (2007) 1.16
Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol (1993) 1.09
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J Virol (1996) 1.01
Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest (1993) 0.98
Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med (1994) 0.98
Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS. J Virol (1998) 0.96
Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 0.88
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest (1993) 0.87
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol (1994) 0.84
Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J Virol (1996) 0.84
Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. J Clin Invest (1994) 0.82
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol (1996) 0.78
A Simple Mouse Model for the Study of Human Immunodeficiency Virus. AIDS Res Hum Retroviruses (2015) 0.76
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression. Clin Diagn Lab Immunol (1995) 0.75
Where are we now with vaccines against AIDS? BMJ (1993) 0.75
Chimps protected from infected cells. Science (1992) 2.22
Aspects of the synthesis of poliovirus RNA and the formation of virus particles. Virology (1966) 5.85
HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature (1987) 5.45
Molecular weight of poliovirus ribonucleic acid. J Virol (1969) 5.16
Rapidly labeled HeLa cell nuclear RNA. I. Identification by zone sedimentation of a heterogeneous fraction separate from ribosomal precursor RNA. J Mol Biol (1966) 4.83
New versatile cloning and sequencing vectors based on bacteriophage M13. Gene (1983) 4.55
The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol (1996) 3.82
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65
The biosynthesis and functional role of cardiolipin. Prog Lipid Res (2000) 3.60
Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature (1984) 3.32
An intermediate in the synthesis of poliovirus RNA. Proc Natl Acad Sci U S A (1966) 3.24
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 3.22
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol (1989) 3.05
Capsid proteins of Simian virus 40. Biochem Biophys Res Commun (1970) 2.91
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A (1984) 2.85
Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J (1988) 2.84
Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature (1992) 2.67
Risk factors for AIDS and HIV seropositivity in homosexual men. Am J Epidemiol (1987) 2.62
Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome. Lancet (1984) 2.56
Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini. DNA (1984) 2.56
A domain of SV40 capsid polypeptide VP1 that specifies migration into the cell nucleus. EMBO J (1986) 2.51
Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS. Lancet (1984) 2.32
Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res (1997) 2.26
Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem (2000) 2.26
Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence. EMBO J (1989) 2.24
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
Universal cellular tropism? Nature (1992) 2.18
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol (1986) 2.17
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med (1999) 2.15
Early determinants of overweight at 4.5 years in a population-based longitudinal study. Int J Obes (Lond) (2006) 2.13
Regulatory mutations of inositol biosynthesis in yeast: isolation of inositol-excreting mutants. Genetics (1982) 2.10
Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med (1994) 2.10
Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins. J Virol (1989) 2.07
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP. Acta Paediatr (2000) 2.02
Percutaneous internal ureteral stent placement: review of technical issues and solutions in 50 consecutive cases. Clin Radiol (1994) 2.01
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
An improved method for sequencing of RNA templates. Nucleic Acids Res (1990) 1.99
Inhibitors of DNA synthesis: their influence on replication and transcription of simian virus 40 DNA. Virology (1974) 1.97
Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci U S A (1991) 1.97
High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol (2000) 1.94
Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus). Biochem Biophys Res Commun (1984) 1.94
Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1. Proc Natl Acad Sci U S A (1983) 1.94
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93
A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol (2000) 1.89
Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng (1988) 1.87
Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Nucleic Acids Res (1995) 1.86
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med (1987) 1.75
Ribosome formation in HeLa cells in the absence of protein synthesis. J Mol Biol (1966) 1.75
Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera. EMBO J (1991) 1.72
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol (1994) 1.72
Analysis of the functional significance of amino acid residues in the putative NTP-binding pattern of the poliovirus 2C protein. J Gen Virol (1992) 1.70
Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet (1985) 1.70
Characterization of a yeast regulatory mutant constitutive for synthesis of inositol-1-phosphate synthase. Mol Gen Genet (1982) 1.70
The effect of HeLa cell cytoplasm on the rate of sedimentation of RNA. Proc Natl Acad Sci U S A (1966) 1.69
In vitro synthesis of poliovirus ribonucleic acid: role of the replicative intermediate. J Virol (1969) 1.68
Mutational analysis of the HIV nef protein. Virology (1990) 1.68
Relationship between replication of simian virus 40 DNA and specific events of the host cell cycle. J Virol (1973) 1.67
Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Res Hum Retroviruses (1993) 1.67
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses (1993) 1.66
Spinal cord tumors in children: long-term results of combined surgical and radiation treatment. J Neurosurg (1994) 1.65
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother (2005) 1.63
Anatomy of the posterior approach to the lumbar plexus block. Can J Anaesth (1994) 1.62
A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1. EMBO J (1983) 1.59
Characterization of the 5' and 3' ends of viral messenger RNAs isolated from BHK21 cells infected with Germiston virus (Bunyavirus). Virology (1990) 1.59
Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol (2001) 1.58
Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol (1993) 1.57
Molecular cloning of the genome of poliovirus type 1. Proc Natl Acad Sci U S A (1981) 1.56
High genetic stability of the region coding for the structural proteins of yellow fever virus strain 17D. J Gen Virol (1987) 1.56
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56
A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc Natl Acad Sci U S A (2000) 1.55
Yeast mutant defective in phosphatidylcholine synthesis. J Bacteriol (1983) 1.55
Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530. Bioorg Med Chem Lett (1998) 1.54
Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am (1994) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. Anesth Analg (1997) 1.52
Isolation of human T-lymphotropic retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodromes. Lancet (1984) 1.51
Facilitating submental endotracheal intubation with an endotracheal tube exchanger. Anesth Analg (2000) 1.49
Thermosensitive block of the Sabin strain of poliovirus type I. J Virol (1972) 1.48
Tumour prevention and rejection with recombinant vaccinia. Nature (1987) 1.47
Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. J Immunol (1992) 1.47
Selective inhibition of in vitro DNA synthesis dependent on phiX174 compared with fd DNA. I. Protein requirements for selective inhibition. J Biol Chem (1977) 1.47
Mercury levels in the Cree population of James Bay, Quebec, from 1988 to 1993/94. CMAJ (1998) 1.46
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 1.46
Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol (1985) 1.45
Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature (1986) 1.45
Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS (1993) 1.44